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Abstract: Upstream open reading frames (uORFs) are
major gene expression regulatory elements. In many
eukaryotic mRNAs, one or more uORFs precede the
initiation codon of the main coding region. Indeed,
several studies have revealed that almost half of human
transcripts present uORFs. Very interesting examples have
shown that these uORFs can impact gene expression of
the downstream main ORF by triggering mRNA decay or
by regulating translation. Also, evidence from recent
genetic and bioinformatic studies implicates disturbed
uORF-mediated translational control in the etiology of
many human diseases, including malignancies, metabolic
or neurologic disorders, and inherited syndromes. In this
review, we will briefly present the mechanisms through
which uORFs regulate gene expression and how they can
impact on the organism’s response to different cell stress
conditions. Then, we will emphasize the importance of
these structures by illustrating, with specific examples,
how disturbed uORF-mediated translational control can
be involved in the etiology of human diseases, giving
special importance to genotype-phenotype correlations.
Identifying and studying more cases of uORF-altering
mutations will help us to understand and establish
genotype-phenotype associations, leading to advance-
ments in diagnosis, prognosis, and treatment of many
human disorders.
Introduction
Regulation of gene expression at the post-transcriptional level is
increasingly being recognized as a key mechanism by which cells
and organisms can rapidly change their gene expression patterns
in response to internal or external stimuli. Emerging examples
illustrate that expression of all genes is regulated at multiple post-
transcriptional steps including mRNA processing, nuclear export
and localization, stability, and translation of mature mRNA
molecules. Translation itself is regulated by a diverse collection of
mechanisms that act at the initiation step, as well as during
elongation and termination and even after termination. Transla-
tional regulation at the initiation step can be mediated via different
cis-acting elements present in the RNA 59 leader sequence of
specific transcripts; these elements include the secondary structure
that is able to inhibit AUG initiation codon recognition due to a
blockage of the scanning ribosome, internal ribosome entry sites
(IRESs) that stimulate cap-independent translation, protein
binding sites that either repress or promote translation in response
to relaying molecular signals, non-AUG initiation codons, the
AUG sequence context that affects efficiency of AUG recognition,
and upstream AUG codons (uAUGs), in some cases, associated
with upstream open reading frames (uORFs). uORFs are
sequences defined by an initiation codon in frame with a
termination codon located upstream or downstream of the main
AUG. uORFs correlate with significantly reduced protein
expression levels because they reduce the efficiency of translation
initiation of the main downstream ORF in unstressed conditions
[1,2], or trigger mRNA decay [3–5]. However, in response to
cellular stress, the presence of uORFs can promote the increased
expression of certain stress-related mRNAs [6]. Nevertheless, there
are other mRNAs for which it has been shown that some or all
uORFs have no effect on translation [7,8]. Indeed, from the
published data, it is apparent that there are different mechanisms,
some of them uORF(s) independent, which can be used by
individual uORF-containing mRNAs to control protein synthesis.
Bioinformatic studies have now shown that about 49% of the
human transcriptome contains uORFs, which are mostly con-
served among species, suggesting evolutionary selection of
functional uORFs [2,9–12]. For example, genes as diverse as
CD36, MDM2, ERBB2, SOC1, and RARB have conserved and
experimentally characterized uORFs that regulate translation
[10]. uORFs are conspicuously common in certain classes of
mRNAs, including two-thirds of oncogenes and many other
transcripts that encode proteins involved in important cellular
processes, such as differentiation, cell cycle, and stress response
[1,6,13–15]. As stated above, it has been suggested that uORFs
are negatively correlated with protein production [2,16], but until
now, functional activity has been demonstrated for only a limited
number of uORFs. Indeed, uORF-mediated translational regula-
tion has been validated experimentally for about 100 eukaryotic
transcripts, including around 30 human transcripts [2]. In
addition, recent studies have described several transcripts where
changes in the 59 leader sequence that disrupt or create a uORF
are associated with the development of human disease or disease
susceptibility, revealing the importance of these cis-acting elements
in gene expression regulation [2]. Bearing in mind the unequivocal
examples already described, it is expected that uORF mutations
may be involved in the genetic architecture of a wide variety of
diseases, including malignancies, metabolic or neurologic disor-
ders, and inherited syndromes.
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In this review, we will briefly present the mechanisms through
which uORFs are thought to regulate gene expression and how
they can impact on the organism’s response to different external
conditions. Then, we will emphasize the importance of these
structures in translational regulation by illustrating, with specific
examples, how disturbed uORF-mediated translational control
can be involved in the etiology of human disease, paying special
attention to genotype-phenotype correlations. Identifying and
studying more cases of uORF-altering mutations will help to
establish and understand genotype-phenotype associations, leading
to advances in diagnosis, prognosis, and treatment of many human
disorders.
uORFs as Translational Regulatory Elements
The process of mRNA translation can be divided into four
stages—initiation, elongation, termination, and ribosome recy-
cling—each of which requires a particular set of conditions and
factors. Translation initiation is the rate-limiting step and, in
eukaryotic cells, requires the participation of several eukaryotic
initiation factors (eIFs) [17]. Canonical translation initiation is
mediated by the recruitment of the cap-binding protein complex,
namely eukaryotic initiation factor 4F (eIF4F), which comprises
eIF4E, eIF4A, and eIF4G, to the mRNA 59 end [18]. eIF4G has a
binding site for eIF4E and the poly(A)-binding protein, which in
turn is bound to the poly(A) tail, resulting in mRNA circularization
[18]. The unwinding of the 59 leader sequence by the ATP-
dependent helicase eIF4A enables binding of the 40S ribosomal
subunit. The association of eIF1, eIF1A, and eIF3 to the 40S
subunit facilitates the binding of the ternary complex eIF2-GTP-
Met-tRNAi [18]. The resulting 43S preinitiation complex can land
next to the cap and scans in a 59 to 39 direction until it recognizes
an AUG codon base pairing with Met-tRNAi [18,19]. Upon
recognition of the start codon, eIF5 stimulates GTP hydrolysis,
resulting in the release of eIF2-GDP and probably other 40S-
bound initiation factors. eIF5B catalyzes the recruitment of the
60S subunit to form an 80S ribosome, and elongation can start
[18,20].
Initially, it was assumed that the scanning 43S preinitiation
complex would generally initiate translation at the first AUG
codon encountered. However, several studies have shown that an
AUG is not always recognized and that there are several factors
that can influence this recognition, such as the sequence context of
the AUG codon or the presence of strong secondary structures
[21]. Indeed, it has been demonstrated that there are specific
nucleotides surrounding the AUG codon whose presence corre-
lates well with the strength of its recognition. The most efficient
context for ribosome recognition and initiation of translation is
known as the Kozak consensus sequence (GCCA/GCCAUGG).
The nucleotides at positions 23 and +4 (underlined) are the most
important ones for the definition of the context strength [22]. In
the presence of a weaker context sequence, a mechanism called
leaky scanning can occur, where the ribosome can either read the
AUG codon or pass by it initiating translation at a downstream
initiation codon [23].
For a uORF to function as a translational regulatory element, its
initiation codon must be recognized, at least at certain times, by
the scanning 40S ribosomal subunit and associated initiation
factors. When uORF recognition is regulated by the so-called
leaky-scanning mechanism, ribosomes either scan through the
upstream AUG codon (Figure 1A) or recognize it, initiating
translation. In the case that the uORF is recognized by a scanning
ribosome, the following alternative fates are available to the
ribosome: (i) translate the uORF and dissociate (Figure 1B); (ii)
translate the uORF and stall during either the elongation or
termination phase of translation, creating a blockage to additional
ribosomes (Figure 1C) or inducing mRNA decay (Figure 1D); or
(iii) translate the uORF and remain associated with the mRNA,
continue scanning, and reinitiate further downstream at either a
proximal or distal AUG codon (Figure 1E). Translation reinitia-
tion is thought to be an inefficient mechanism that happens only
after translation of a short ORF [24]. Indeed, reinitiation is
dependent on (i) the time required for the uORF translation,
which is determined by the relative length of the uORF and the
translation elongation rate; and (ii) the translation initiation factors
involved in the translation initiation event [23,25]. Several
initiation factors need to remain associated with the ribosome
during translation and even after the termination event so that
reinitiation can occur [26,27]. In this way, a ribosome that
translates a shorter uORF (or with a higher translation rate) is
more likely to reinitiate translation [25]. A key factor for
translation reinitiation is the reacquisition of a new ternary
complex (eIF2-GTP-Met-tRNAi); this complex is essential for the
recognition of a downstream AUG by the scanning 40S subunit
[28]. In fact, many studies have reported that longer intercistronic
regions are more favorable for reinitiation, while for shorter ones
the scanning time may not be sufficient for reacquisition of the
ternary complex and the downstream AUG will therefore not be
recognized [26,27,29]. The basis for the mechanism of translation
reinitiation has not been completely elucidated. Therefore, it is
essential to define more precisely which initiation factors promote
reinitiation competence, as well as potential changes in the
ribosomes that may be involved in this process.
As already stated, an additional feature of uORFs is their
capacity to block the translational machinery in a peptide-
dependent manner [30]; this might result in the stalling of other
ribosomes that access the transcript, thereby dramatically
decreasing the translation of the main ORF [31]. Examples of
uORFs that function in a sequence-dependent manner are the
receptor-like protein-tyrosine phosphatase J (PTPRJ) [32], the b2-
adrenergic receptor, and the S-adenosylmethionine decarboxylase
(AdoMetDC) [33]. The few examples described in mammals make it
difficult to identify the conserved peptide sequences responsible,
and identification of further uORFs with this ability is only
possible experimentally. One study comparing full-length cDNA
sequences from different plant species aiming to identify conserved
peptide uORF sequences found that uORFs rich in serine,
threonine, and/or tyrosine were present in nine homologous
groups [34]. These amino acids are potential targets for
phosphorylation that could possibly promote or inhibit ribosome
stalling or translation initiation at downstream ORFs. Neverthe-
less, further characterization of this type of uORF is necessary
before a consensus sequence can be annotated.
Despite the obvious complexity of uORF-mediated translational
regulation, results from several studies have revealed that the
impact the uORFs can have on translation depends on several
variables, such as (i) the distance between the 59 cap and the
uORF, (ii) the context in which the uORF AUG is located, (iii) the
length of the uORF, (iv) the secondary structure of the uORF, (v)
conservation among species, (vi) the number of uORFs per
transcript, (vii) the position of the uORF termination codon,
upstream or downstream of the main initiation codon, and (viii)
the length of the intercistronic sequence(s) (Figure 1F). Although
all types of uORF can reduce protein expression in unstressed
cells, four uORF properties are associated with greater transla-
tional inhibition; these are: strong uAUG context, evolutionary
conservation, increased distance from the cap, and multiple
uORFs in the 59 leader sequence [2]. These properties reflect the
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impact that uORF(s) have in translational efficiency of the main
ORF, when they are translated.
It is still unclear whether uORF-encoded peptides can play
additional roles in the cell. Conceivably, uORF-encoded peptides
could act both as translational regulators of the main ORF and as
trans-acting factors in the cell. Further characterization of
conserved uORFs might help to resolve this hypothesis.
uORFs and mRNA Decay
The similarity between the cistronic organization of uORF-
containing mRNAs to that of mRNAs containing a nonsense
mutation has suggested the potential of the former to trigger the
nonsense-mediated decay (NMD) pathway. NMD is one of the
better characterized quality control mechanisms which acts as an
mRNA surveillance pathway by degrading transcripts harboring
premature translation termination codons (PTCs) [35]. However,
in the last decade, several studies have also implicated NMD in the
regulation of steady-state levels of physiological mRNAs, and
many examples of natural NMD targets are indeed transcripts
containing uORFs [3–5,36], in which the uORF termination
codon can be recognized as premature. The major challenge for
this translation-dependent mechanism is to discriminate between a
premature and a normal termination codon. This discrimination
occurs when the ribosome is poised at the termination codon.
According to current models, normal translation termination
involves the interaction of the eukaryotic release factor 3 (eRF3)
with the poly(A) binding protein cytoplasmic 1 (PABPC1) at the
terminating ribosome, which stimulates a proper and efficient
translation termination event [37–39]. However, if the termination
codon location within a certain messenger ribonucleoprotein
(mRNP) context does not allow PABPC1 to interact with eRF3,
the terminating ribosome will stall, allowing its interaction with the
NMD effector UPF1 and triggering NMD [40]. The ‘‘unified
model’’ for NMD proposes that there are several features in the
mRNP that can trigger the NMD response. For example, PTCs
Figure 1. uORF-mediated translational control can occur through different mechanisms. (A) The leaky scanning mechanism is dependent
on the efficiency of uAUG recognition; sometimes the ribosome can translate the uORF, but other times the scanning machinery bypasses the uAUG,
recognizing the downstream AUG and translating the main ORF. (B) When a scanning ribosome recognizes and translates a functional uORF, there is
synthesis of a small peptide; if translation termination of the uORF is efficient, both 60S and 40S ribosomal subunits might dissociate from the
transcript and the main ORF is not translated. (C) A uORF can repress translation of the main ORF in a peptide-dependent manner; in this case, the
uORF-encoded peptide interacts with the translating machinery and promotes ribosome blockage. (D) The termination codon of a uORF can be
recognized as premature and nonsense-mediated mRNA decay (NMD) is triggered through a mechanism involving the UPF1 protein and
ribonucleases. (E) After translation termination of the uORF, the 40S ribosomal subunit can remain associated with the transcript, resume scanning,
and recognize the downstream main AUG—a mechanism designated as translation reinitiation. (F) The impact that the uORFs can have on
translation depends on (i) distance between the 59 cap (m7G) and the uORF (distance to the cap), (ii) context in which the uORF AUG is located (AUG
context), (iii) length of the uORF, (iv) number of uORFs per transcript, (v) secondary structure of the uORF, (vi) conservation among species, (vii) length
of the intercistronic sequence(s), and (viii) position of the uORF termination codon, upstream or downstream of the main initiation codon (length,
number, secondary structure, conservation, position of stop codon). The increase of translational repression exerted by a uORF correlates with
increasing distance between the m7G and the uORF, increasing length of the uORF and intercistronic sequence, a higher number of uORFs, and a
stronger uAUG Kozak context. (G) In response to stress conditions, the presence of more than one uORF in a transcript can promote an increase in
translation efficiency of the main ORF; the reinitiation after translation of the uORF1 is less efficient since there is less ternary complex available.
Consequently, reinitiation will take more time/distance to occur and the ternary complex will only be available by the time the 40S ribosomal subunit
has already bypassed the subsequent uORFs, augmenting the recognition of the main AUG. (H) In response to stress conditions, the presence of one
uORF in a transcript can promote an increase of the corresponding protein levels; the higher levels of phosphorylated eIF2a contribute to increase
leaky scanning of the uORF and translation of the main ORF is favored.
doi:10.1371/journal.pgen.1003529.g001
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located at a greater distance from the poly(A) tail, as is the case for
mRNAs harboring long 39UTRs, can elicit NMD due to PABPC1
failing to interact with the termination complex [40–43]. Another
NMD-triggering feature is the presence of at least one exon-exon
junction more than 50 nucleotides downstream of the termination
codon [44]. During splicing, the exon junctions are marked with a
dynamic multiprotein complex designated exon-junction complex
(EJC) that associates with the NMD factors UPF2 and UPF3 [45].
The presence of an EJC downstream of a termination codon
allows the interplay between UPF1 at the terminating ribosome
and UPF2 and/or UPF3, which results in UPF1 phosphorylation,
irreversibly triggering NMD [46]. Consequently, PTCs located
far, in a linear sense, from the poly(A) tail and associated PABPC1,
in mRNAs containing residual downstream EJCs, are expected to
elicit NMD [40–43]. Nevertheless, we have reported that AUG-
proximal nonsense-mutated mRNAs evade NMD [47–50]. In
such cases, there is establishment of an efficient translation
termination event because of the ability of PABPC1 to travel with
the ribosome, due to interactions with eIF4G and eIF3. This
allows a repositioning of the PABPC1/eIF4G/eIF3 protein
complex in the vicinity of the PTC at the translation termination
event, blunting the NMD response and eliciting efficient
termination [51]. Because the PABPC1/eIF4G/eIF3 complex
might still be bound to the ribosome when it reaches the stop
codon of a small ORF, eIF3 is in a favored position to promote
reinitiation competence; as these interactions might be disrupted
after some steps of translation elongation, transcripts carrying
smaller ORFs are more competent for translation reinitiation than
those with larger uORFs.
The termination codon of a uORF can be recognized as a PTC
since it is distant from the 39UTR signals and the corresponding
transcript usually presents downstream EJCs located in the coding
sequence of the main ORF [21,52]. Examples of human
transcripts whose uORFs trigger NMD are the interferon-related
developmental regulator 1 (IFRD1) [53], the cystic fibrosis
transmembrane conductance regulator (CFTR) [54], and SMG5
[5]. However, some naturally occurring uORF-containing tran-
scripts escape NMD. Indeed, uORFs often mediate translational
repression of the protein coding ORF without an associated
decrease in mRNA levels [21,52]. The length of the uORF and the
time taken to translate it are characteristics that influence the
triggering of NMD (our unpublished data). According to our
model [43], only transcripts harboring at least one uORF with a
critical length would trigger NMD, while those with smaller
uORF(s) could be NMD-resistant because of PABPC1 proximity
to the uORF termination codon due to mRNA circularization
during translation [50,51]. In mammalian cells, the minimum size
of the uORF that triggers NMD has been difficult to determine
[3]; however, in plants, 35 codons is the threshold [55]: transcripts
with longer uORFs are NMD-sensitive and those with shorter
uORFs are NMD-resistant. Also, in plants, increasing the
reinitiation predisposition has no effect on NMD, which contra-
dicts the notion that reinitiation would prevent the destabilization
of the mRNA [55]. Nevertheless, in mammalian cells, some
transcripts with long uORFs, which are NMD-targets under
normal circumstances, become resistant to NMD during stress
conditions, depending on the phosphorylation of eIF2a [53,56].
IFRD1 is a documented example of a uORF with 52 codons that
responds to the phosphorylation of eIF2a by increasing mRNA
stability [53]. One possible explanation for NMD inhibition in
response to eIF2a phosphorylation is that under these conditions,
leaky scanning through the uORF increases and thus the
corresponding stop codon is not recognized, which impairs
NMD. This example illustrates how complex and puzzling the
inhibitory effect of a uORF and the response to stress conditions
can be. In any case, these data demonstrate that cells have evolved
different mechanisms that contribute to the integrated stress
response, among which inhibition of NMD also contributes to
increased expression of stress-response proteins.
uORFs and the Cellular Response to Stress
Conditions
Translational regulation mechanisms are able to mediate rapid
and reversible changes in protein expression as a cellular response
to internal and external stimuli. One of the most commonly used
mechanisms for inhibiting global translation is by phosphorylation
of the initiation factor eIF2 [57]. In order to be recycled, eIF2 is
recharged with GTP by the guanine nucleotide exchange factor
(GEF) eIF2B. However, when eIF2 is phosphorylated on serine 51
of its a subunit, it becomes a competitive inhibitor of eIF2B,
preventing eIF2 recycling and reducing translation initiation rates
by lowering the ternary complex concentration [57]. In mamma-
lian cells, phosphorylation of eIF2a on serine 51 is a major
mechanism that regulates initiation of translation in response to
various cellular stresses, including virus infection, nutrient
deprivation, iron deficiency, and accumulation of unfolded
proteins in the endoplasmic reticulum (ER) [57]. Depending on
the specific cellular stress, eIF2a is phosphorylated by at least four
different kinases, including double-stranded RNA-activated kinase
(PKR), general control non-derepressible 2 kinase (GCN2), heme-
regulated inhibitor kinase (HRI), and PKR-like ER kinase
(PERK). Following stress-induced eIF2a phosphorylation, trans-
lation of normal cellular mRNAs is repressed, while the
translational initiation of selected mRNAs involved in stress
response is stimulated [57].
A second mechanism for nonspecifically reducing levels of
protein synthesis involves interfering with m7G cap recognition,
thereby preventing recruitment of the translational machinery to
the mRNA [58]. The m7G cap is recognized by eIF4E as part of
the eIF4F complex; however, there are several eIF4E-binding
proteins (4E-BPs) which compete with eIF4G for a binding site on
eIF4E and prevent eIF4F complex formation [59]. The strength of
binding of 4E-BPs to eIF4E is controlled by phosphorylation:
hypophosphorylated 4E-BPs bind strongly, while phosphorylated
4E-BPs bind weakly.
As stated above, accumulating evidence has revealed that in
response to abnormal stimuli, general translation is inhibited.
However, alternative mechanisms of translation initiation and
translational control act to maintain the synthesis of certain
proteins required either for the stress response or to aid recovery
from stress. These pathways are evolutionarily conserved and have
been shown to significantly impact translation in organisms as
diverse as yeast and humans. In many cases, features in the 59
leader sequence of the corresponding mRNAs, such as IRESs and
regulatory uORFs, are important for them to evade global
repression of translation. For example, when eIF2 is phosphory-
lated and consequently global translation is inhibited, the presence
of uORF(s) in a transcript can promote an increase in the
corresponding protein levels (Figure 1G and Figure 1H). The yeast
transcription factor GCN4 is one of the better studied examples of a
transcript containing uORFs that are able to respond to cell stress.
This transcript harbors four uORFs in its 59 leader sequence. The
first of the four uORFs is always efficiently translated regardless of
the nutritional conditions. In unperturbed cells, rapid reloading of
ribosomes and initiation cofactors allows translation of uORFs 2–4
while inhibiting the translation of the main ORF. In conditions of
amino acid starvation, reinitiation after translation of the uORF1
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is less efficient since there is less ternary complex available.
Consequently, reinitiation will take more time/distance to occur
and the ternary complex will only be available by the time the 40S
ribosomal subunit has already bypassed the subsequent uORFs,
thereby augmenting the recognition of the main AUG [60]. This
mechanism allows a fast response to nutritional stress [61,62]. The
stress response gene that encodes the activating transcription
factor 4 (ATF4) is the prototypical mammalian example of this
type of regulation [63]. ATF4 promotes transcriptional upregula-
tion of specific target genes in response to cellular stress. ATF4
expression at the translational level is regulated by two uORFs,
with the second overlapping the AUG of the ATF4 coding
sequence, although in a different reading frame (Figure 2). Under
normal conditions, when eIF2a is not phosphorylated and ternary
complex is not limiting, the scanning preinitiation complex
recognizes the first uORF and translates a short peptide, and
the 60S ribosome dissociates upon reaching the stop codon
marking the end of the uORF. The 40S ribosomal subunit that
remains associated with the mRNA is then able to recruit ternary
complex and initiate translation of the second uORF. Because the
second uORF overlaps with the main coding sequence, this
prevents translation of the ATF4 coding sequence. However, in
conditions of reduced ternary complex availability, initiation of the
second uORF is less likely, as there is less chance of the scanning
ribosomal subunit recruiting the ternary complex required for start
codon recognition [63,64] (Figure 2). By this mechanism, a
reduction in active eIF2 induces increased protein expression from
mRNAs carrying the correct arrangement of uORFs (Figure 1G
and Figure 1H) [65,66]. This is also the case for the human ATF5
[67]; like ATF4, ATF5 is a transcription factor of the cAMP-
response element binding protein (CREB)/ATF family, which is
encoded by two transcripts (ATF5a and ATF5b) with alternative 59
leader sequences [68]. The 59 leader sequences of ATF4 and
ATF5a have similar configurations and both contain two
conserved uORFs [64,66–68] (Figure 2). Similar to what occurs
in the ATF4 mRNA, the ATF5a uORFs are involved in protecting
Figure 2. Examples of human genes encoding mRNAs that, under stress conditions, evade global repression of translation and are
upregulated due to the presence of uORFs. For each mRNA, the schematic representation of the 59 leader sequence is shown with the length
(in nucleotides; nts) indicated below each representation; boxes with numbers represent the uORF(s), where the number indicates the corresponding
length in codons.
doi:10.1371/journal.pgen.1003529.g002
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cells from amino acid limitation, as well as from arsenite-induced
oxidative stress, through phosphorylation of eIF2a [67]. Interest-
ingly, the regulatory mechanisms governing variable ATF4 and
ATF5 expression in response to eIF2a phosphorylation, under
different conditions of stress, are likely due to a combined effect of
translational and transcriptional control of ATF4 and ATF5
mRNAs. In addition, global cellular adaptation to stress includes
the transcriptional upregulation of ATF4 and ATF5 targets.
Nevertheless, other genes activated by eIF2a phosphorylation may
also function in conjunction with ATF4 and ATF5, as well as their
targets.
As stated, genes with uORFs in their transcripts are good
candidates to be upregulated in response to eIF2a phosphoryla-
tion. An example of regulated expression via uORF(s) is the
carnitine palmitoyltransferase 1C (CPT1C) gene (Figure 2).
CPT1C regulates metabolism in the brain in situations of energy
surplus. The presence of a uORF in the 59 leader sequence
represses the expression of the main ORF. However, this
repression is relieved in response to specific stress stimuli like
glucose deprivation and palmitate-BSA treatment [69]. The
mRNAs that encode the CCAAT/enhancer-binding protein
homologous protein (CHOP) [70,71], growth arrest DNA-induc-
ible gene 34 (GADD34) [72], and b-site APP (amyloid precursor
protein) cleavage enzyme 1 (BACE1) [73,74] are also examples
where the phosphorylation of eIF2a is responsible for the
translational derepression (Figure 2). The majority of these
transcripts bear more than one uORF, resulting in an effect
similar to the one seen in GCN4, ATF4, or ATF5a (see above).
Although it seems that transcripts with only one uORF can also be
regulated by this mechanism as is the case for the CHOP transcript,
the underlying molecular basis for this remains poorly understood.
Chen et al. have reported that in cells under anisomycin
treatment, uORF-mediated CHOP translation is controlled by
the dissociation of phosphorylated eIF4E from 4E-BP. A key
finding of this study is that the phosphorylation of both eIF4E and
eIF2a is crucial for CHOP stress-responsive translational regulation
[71]. These authors also showed that anisomycin activates both
Mnks and mTOR signaling pathways which converge at eIF4E for
CHOP uORF-mediated translation, in addition to phosphorylated
eIF2a [71]. Despite the fact that many questions still need to be
answered, these two pathways have been implicated in the
induction of translation of uORF-containing transcripts, such as
protein kinase C [75], ATF4 [66] in response to amino acid
starvation, CITED2 [76] in response to hypoxia, or CPT1C [69] in
response to specific stress stimuli, namely glucose deprivation and
palmitate-BSA treatment.
In addition, vascular endothelial growth factor A (VEGF-A) [77],
p27 [78], endothelial cell tyrosine kinase receptor (TIE2) [79], N-
deacetylase/N-sulfotransferase (NDST) [80], and cationic amino
acid transporter 1 (CAT1) [81,82] provide other examples of
transcripts regulated by functional uORFs (Figure 2); however, it is
interesting to note that in these cases, uORFs are located within an
IRES, which is translated through a cap-independent mechanism.
In the case of CAT1 mRNA, it has been demonstrated that
induction of IRES activity requires the translation of the uORF
located within the IRES [82]. The translation of the uORF
unfolds an inhibitory structure in the mRNA 59 leader sequence,
creating an active IRES through RNA-RNA interactions between
the 59 end of the leader sequence and downstream sequences,
which increases CAT1 protein synthesis [82].
There are other interesting examples of how cis-acting elements
and different gene expression mechanisms can act together for a
specific outcome [83–85] (Figure 2). In the case of the tribbles
homolog 3 (TRB3) gene, in response to arsenite exposure, there is
binding of ATF4 to the promoter which leads to a switch in
promoter usage; this results in the production of a transcript with
no uORF, while under normal conditions two transcripts are
produced: one with a uORF in the 59 leader sequence and one
with no uORF [83]. For the C/EBPa gene, 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO) augments C/EBPa
activity in acute myeloid leukemia cells by translationally
enhancing the p42/p30 C/EBPa isoform ratio in a C/EBPa
uORF-dependent manner [84]. In another case, high glucose
conditions increase CD36 mRNA translational efficiency that
results in increased expression of the macrophage scavenger
receptor CD36, due to ribosomal reinitiation following translation
of a uORF. Increased translation of the macrophage CD36
transcript provides a mechanism for accelerated atherosclerosis in
diabetics [85].
A final example is the HER2 oncogene that encodes a 185 kDa
transmembrane receptor tyrosine kinase. HER2 overexpression
occurs in numerous primary human tumors and contributes to 25–
30% of breast and ovarian carcinomas. Synthesis of HER2 is
controlled in part by a uORF that represses translation of the
downstream main coding region. HER2 overexpression in cancer
cells seems to be due to an interaction of 39UTR with the uORF
through an RNA-binding protein, thus overriding translational
inhibition mediated by the HER2 uORF [86]. Even though the
precise mechanism by which this interaction occurs is still
unknown, it provides further evidence of how uORFs and other
gene expression pathways can act together for the modulation of
the expression of regulatory genes and of the individual
phenotype. In addition, the examples shown here suggest that
the translational control mediated by uORFs may involve several
steps of mRNA metabolism, may include unfolding of mRNA
structures, specific sequences, or trans-acting factors, may occur in
a context-dependent manner, and may respond differently to
stress-activated translation initiation factors.
uORFs and Human Disease
Given that uORFs reduce translational efficiency, it is clear that
polymorphisms or mutations that create, disrupt, or modify
uORFs are likely to affect protein expression and may impact
individual phenotypes. Indeed, when Calvo and colleagues
searched for uORF-altering variants within 12 million single
nucleotide polymorphisms (SNPs) in the human dbSNP database
[2,87], they identified uORFs created or deleted by a polymor-
phism in 509 genes; 366 of these genes encode transcripts
harboring multiple uORFs, whereas the remaining 143 mRNAs
have a single uORF [2]. This study also showed that these uORFs
induce a 30–60% decrease in protein levels when compared to the
protein levels expressed from the corresponding allele without the
uORF-altering SNP variant [2]. As a concrete example, an SNP
was described that alters the human clotting factor XII (FXII) 59
leader sequence, and has been associated with several thrombo-
embolic conditions due to differences in circulating FXII plasma
levels [88]. This SNP consists of a common C to T polymorphism
with prevalence of the T allele estimated at 20% in Caucasian and
70% in Asian populations [89,90]. It is located at position 24 of
the FXII 59 leader sequence (where the A of the main AUG start
codon is nucleotide +1), introduces a very short uORF (with 2
codons), and simultaneously alters the AUG Kozak sequence
context of the factor FXII coding sequence. Kanaji and colleagues
have experimentally confirmed that the T allele does not affect
mRNA levels, but reduces protein levels by about 50%, increasing
the predisposition to thrombosis [90]. More recently, it was
demonstrated that this protein reduction is indeed due to the
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Table 1. Examples of human diseases associated with polymorphisms or mutations that introduce/eliminate uORFs or modify the
encoded uORF peptide.
Disease Gene Mode of Pathogenesis Reference
Polymorphisms/mutations that create uORFs
1. Thrombotic predisposition FXII The -4C to T polymorphism creates a uORF that reduces mRNA translation
efficiency from the main ORF(a)
[2,88–90]
2. b-Thalassemia HBB The -29G to A mutation creates a new translation initiation codon in a favorable
Kozak consensus sequence, which leads to the introduction of a new uORF that
overlaps with the main ORF, but out of frame, and decreases translation efficiency
from the main ORF(a)
[2,91]
3. Carney complex type 1 PRKAR1A The -97G to A mutation creates a uORF that overlaps with the main ORF, but
out of frame, and decreases translation efficiency from the main ORF(a)
[2]
4. Van der Woude syndrome IRF6 The -48A to T mutation creates a uORF that overlaps with the main ORF, but
out of frame, and decreases translation efficiency from the main ORF(a)
[2,92]
5. Gonadal dysgenesis SRY The -75G to A mutation creates a second uORF and reduces mRNA translation
efficiency from the main ORF(a)
[2,93]
6. Hereditary pancreatitis SPINK1 The -53C to T mutation creates a uORF and reduces mRNA translation efficiency
from the main ORF(a)
[2,94]
7. Melanoma predisposition CDKN2A Both described -21C to T and -34G to T mutations create a uORF that reduces
mRNA translation efficiency from the main ORF(a)
[95,96]
8. Familial hypercholesterolemia LDLR A single C nucleotide deletion (at position -22) creates a uORF and reduces
mRNA translation efficiency from the main ORF(b)
[97]
9. Disseminated bronchiectasis CFTR The -34C to T mutation creates a uORF overlapping, but out of frame, with the
CFTR protein coding sequence, which decreases gene expression by reducing
mRNA stability and translation efficiency from the main ORF(a)
[98]
10. Congenital hyperinsulinism KCNJ11 The -54C to T mutation creates a new translation initiation codon in a favorable
Kozak consensus sequence, which leads to the introduction of a new uORF that
overlaps with the main ORF, but out of frame, and decreases translation efficiency
from the main ORF(b)
[99]
11. Rhizomelic chondrodysplasia punctata PEX7 The -45C to T mutation creates a new translation initiation codon in a favorable
Kozak consensus sequence, which leads to the introduction of a new uORF that
overlaps with the main ORF, but out of frame, and decreases translation efficiency
from the main ORF(b)
[100]
12. Proopiomelanocortin deficiency POMC The -11C to A mutation creates a new translation initiation codon in a favorable
Kozak consensus sequence, which leads to the introduction of a new uORF that
overlaps with the main ORF, but out of frame, and decreases translation efficiency
from the main ORF(b)
[101]
13. Levodopa responsive dystonia GCH1 The -22C to T mutation creates a new translation initiation codon that leads to
the introduction of a new uORF overlapping with the main ORF, but out of
frame, and decreases translation efficiency from the main ORF(b)
[102]
14. Juvenile hemochromatosis HAMP The -25G to A mutation creates a new translation initiation codon, which leads to
the introduction of a new uORF overlapping with the physiological ORF, but out
of frame, and decreases translation efficiency from the main ORF(a)
[103]
Polymorphisms/mutations that disrupt uORFs
15. Marie Unna hereditary hypotrichosis HR The -321A to G mutation disrupts one of the existing uORFs and results in an
increased translational efficiency of the main HR physiological ORF(a)
[104,105]
16. Thrombocythemia TPO -31G to T mutation generates a new stop codon in uORF 7 and thereby shortens
uORF 7 by 42 nucleotides. The truncated uORF 7 no longer extends past the
physiological initiation codon, and thus it improves translational efficiency by
allowing translation reinitiation(a)
[106–109]
The G to C transversion in the splice donor site of intron 3 of the TPO gene leads
to mRNAs with shortened 59 leader sequence that are more efficiently translated
than the normal TPO transcripts because they lack uORF 7, which normally inhibits
translation; a novel N-terminus is created by fusion of uORF 5 with the TPO coding
sequence(a)
[110]
A single G nucleotide deletion (at position -50) in the 59 leader sequence of the
TPO gene causes a frameshift in the 59 leader sequence of TPO mRNA that places
uORF 7 in frame with the TPO coding sequence, neutralizing the strong inhibitory
effect of uORF 7 and creating a novel N-terminus for the TPO protein(a)
[111]
Polymorphisms/mutations that modify the encoded uORF peptide
17. Schizophrenia predisposition DRD3 The -204A to G polymorphism within a 36-codon uORF originates a Lys9Glu
amino acid substitution in the uORF-encoded peptide that might decrease
efficiency of ribosomal blockage; this change causes an increase in the DRD3
protein levels(b)
[112]
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presence of the 2-codon uORF, while the disruption of the Kozak
consensus sequence is not responsible for the observed variation in
human FXII protein levels [2] (Table 1). This example shows how
SNPs, found through genetic analyses in the 59 leader sequence of
transcripts, cannot be disregarded, as even if they do not affect
mRNA levels they can affect protein levels and be associated with
human disease. This region should, therefore, be systematically
explored when investigating the molecular mechanism of a
disease.
In addition to polymorphisms that can affect uORFs, rare
mutations that create or disrupt uORFs may also cause disease, as
has been shown for several human genes [2,91–115] (Table 1).
Indeed, several mutations that eliminate or create uORFs that
alter protein levels have been associated with human disease.
Calvo and colleagues have experimentally demonstrated, in five
genes (HBB, PRKAR1A, IRF6, SRY, and SPINK1), that mutations
that create a uORF decrease protein expression levels to 30%, or
less, of those from the normal allele, and these reduced protein
levels are responsible for the associated disease phenotype [2].
Notably, with the SRY and SPINK1 genes, the mutation creates a
second uORF within the 59 leader sequence. Thus, the strong
suppression of protein expression by these mutations offers a
simple mechanistic basis for their pathogenicity [2]. Another study
has shown that predisposition to melanoma can be caused by
mutations that introduce a uORF into the 59 leader sequence of
the mRNA encoding the cyclin-dependent kinase inhibitor protein
(CDKN2A) [95,96]. Other examples of human diseases associated
with mutations that create a uORF include familial hypercholes-
terolemia (low-density lipoprotein receptor gene; LDLR) [97],
cystic fibrosis (CFTR) [98], congenital hyperinsulinism (potassium
inwardly-rectifying channel, subfamily J, member 11; KCNJ11)
[99], rhizomelic chondrodysplasia punctata (peroxisomal biogen-
esis factor 7; PEX7) [100], proopiomelanocortin deficiency
syndrome (proopiomelanocortin; POMC) [101], levodopa-respon-
sive dystonia (guanosine triphosphate cyclohydrolase I; GCH1)
[102], and juvenile hemochromatosis (hepcidin; HAMP) [103]
(Table 1). Although the majority of the polymorphisms/mutations
referred to here that create a uORF have been experimentally
tested for their influence on translation, in the case of LDLR,
KCNJ11, PEX7, POMC, and GCH1 mRNAs, further studies are
needed to confirm the effect of the corresponding mutation on
translational efficiency (Table 1).
Contrary to the effect of mutations that create a uORF, the
repression exerted by a functional uORF can be modulated by
mutations, or alternative processing of the transcript, that disrupt
the uORF, thus influencing the translational rate of the main
ORF. In either case, there is a change in organism homeostasis
that affects individual phenotype. An illustration of a genetic
alteration that disrupts a uORF is a mutation described in the
initiation codon of an inhibitory 34-codon uORF located in the 59
leader sequence of the mRNA that encodes the human hairless
homolog (HR) protein. This mutation has been associated with the
symptomatic condition of Marie Unna hereditary hypotrichosis,
which is a rare autosomal dominant form of genetic hair loss
[104,105]. Functional analysis showed that this mutation results in
increased translation of the main HR physiological ORF
[104,105]. Another noteworthy example is the thrombopoietin
(TPO) gene [106]. Translation of TPO mRNA is physiologically
strongly inhibited by the presence of seven uORFs in its 59 leader
sequence. Directed mutagenesis of all uAUGs in the TPO mRNA
restores translational efficiency, demonstrating that translational
inhibition of TPO biosynthesis is entirely mediated by uORFs
[106]. The uORF defined by the seventh uAUG was shown to
exert the strongest negative effect on translation. This uAUG is in
a good Kozak consensus context and the uORF extends beyond
the physiological start site, thus preventing reinitiation [106].
Table 1. Cont.
Disease Gene Mode of Pathogenesis Reference
18. Aspirin-exacerbated respiratory disease WDR46 The -36G to A polymorphism originates a Gly18Arg amino acid substitution in
the uORF-encoded peptide(b)
[113]
19. Arrhythmogenic right ventricular cardiomyopathy TGFb3 The -30G to A mutation within an 88-codon uORF originates a Arg36His amino
acid substitution in a putative 88–amino acid inhibitory peptide encoded by the
uORF; this change causes an increase in the TGF-b3 protein levels(a)
[114]
20. Bipolar affective disorder and major depression HT3A -42C to T mutation originates a Pro16Ser amino acid substitution in the
uORF-encoded peptide and is postulated to decrease the efficiency of the
uORF repression causing an increase in the HT3A protein levels(a)
[115]
Other alterations
21. Acute myeloid leukemia C/EBPa The C/EBPa uORF modulates the expression ratio of three N-terminally distinct
protein isoforms that are translated from subsequent in frame initiation codons
within the C/EBPa transcript; an increase in expression of the shorter isoform is
associated with acute myeloid leukemia(a)
[116]
22. Breast cancer C/EBPb The C/EBPb uORF modulates the expression ratio of three N-terminally distinct
protein isoforms that are translated from subsequent in frame initiation codons
within the C/EBPb transcript; an increase in expression of the shorter isoform
due to the inactivation of the uORF is associated with breast cancer(a)
[116,117]
23. Several tumors MDM2 A switch in promoter usage favors transcription of an isoform without uORFs
which overexpresses MDM2 protein in comparison with what occurs in normal
cells, where one isoform with two uORFs is mainly expressed(a)
[119]
24. Alzheimer’s disease BACE1 Elevated levels of phosphorylated eIF2a induce a bypass of the inhibitory
mechanism exerted by BACE1 uORFs, which leads to enhanced BACE1 expression(a)
[120,121]
Position of the mutation is relative to the main AUG start codon, where the A is nucleotide +1.
(a)It has been experimentally tested to affect translational efficiency.
(b)It is not experimentally tested.
doi:10.1371/journal.pgen.1003529.t001
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Mutations in the 59 leader sequence of the TPO gene, which cause
hereditary thrombocytosis, inactivate the inhibitory function of
uORF 7 and abolish this translational control [106–111]. In these
cases, pathologically high TPO levels are observed, leading to an
increased number of platelets in the peripheral blood and
increased thrombosis risk. One particular mutation was demon-
strated to introduce a translation termination codon in the 59
leader sequence in frame with uORF 7. As the new in frame stop
codon produces a uORF entirely located in 59 leader sequence, it
confers the ability to reinitiate at the main ORF. This new
regulation mechanism by uORF 7 produces a weaker translational
repression, causing an increase of the TPO protein levels [107–
109]. In another case, a point mutation (G to C transversion) in
the +1 position of the splice donor site of intron 3 causes exon
skipping and results in loss of exon 3 that normally encodes a large
part of the 59 leader sequence. As a consequence, the mutant TPO
mRNA lacks uORF 7, which normally inhibits translation, and
encodes a novel N-terminus created by fusion of uORF 5 with the
TPO coding sequence [110]. A different mutation consists of a
single G nucleotide deletion in the 59 leader sequence of the TPO
gene that causes a frameshift in the 59 leader sequence of TPO
mRNA, which places uORF 7 in frame with the TPO coding
sequence, neutralizing the strong inhibitory effect of uORF 7 and
creating a novel N-terminus for the TPO protein [111]. These
data clearly illustrate how TPO expression is tightly regulated at
the translational level.
As mentioned above, uORFs may differ in their efficiency and
in the mechanisms by which they exert translational repression of
the main ORF. In some cases uORFs repress translation because
the corresponding encoded peptide is able to promote a blockage
in the translating ribosome [30]. Consequently, specific nucleotide
substitutions that alter the uORF coding sequence and originate
an amino acid substitution might affect the efficiency of ribosomal
blockage and thus protein expression from the main ORF. For
example, amino acid substitutions that decrease efficiency of
ribosomal blockage might decrease the translational repression
exerted by the uORF, and therefore they might increase protein
levels, which might lead to clinical manifestations. This is the case
for the human dopamine D3 receptor (DRD3) gene [112].
Sivagnanasundaram and colleagues have screened for polymor-
phisms to assess their contribution to the association of DRD3 with
schizophrenia. Their data have shown that one of the SNPs found
in the 59 leader sequence encodes a change of one amino acid
residue from lysine to glutamic acid within a 36-codon uORF,
which correlates to an increased schizophrenia predisposition
[112] (Table 1). Another example is the G to A transition
described in the WDR46 gene that originates an amino acid
change from glycine to arginine at codon 18 of a uORF in the
WDR46 transcript; this variant is associated with higher risk of
aspirin-exacerbated respiratory disease [113] (Table 1). In a
different study, authors identified the transforming growth factor-
b3 (TGFb3) gene as being involved in arrhythmogenic right
ventricular cardiomyopathy, a progressive and genetically deter-
mined myocardial disease, due to a G to A transition in the TGFb3
59 leader sequence, which leads to an arginine to histidine
substitution at codon 36 of a uORF with 88 codons; it has been
experimentally proven that this change causes an increase in the
TGFb3 protein levels [114] (Table 1). Moreover, the human HT3A
mRNA, which encodes the subunit A of the type 3 receptor for 5-
hydroxytryptamine (serotonin), contains two uORFs, in frame
with the main ORF. A -42C to T mutation in the second uORF of
HT3A is associated with bipolar affective disorder and major
depression; it has been experimentally shown that this mutation
increases translation efficiency of the 5-HT3A subunit [115]
(Table 1). For these pathologies, elucidating the mechanisms
through which uORFs can affect downstream translational
efficiency, depending on the amino acid sequence of the uORF-
encoded peptide, may constitute a tool for the development of new
and more effective drug treatments.
Another intriguing regulatory function of uORFs is observed
in transcripts harboring alternative downstream initiation
codons within their main ORF. This is exemplified by
CCAAT/enhancer binding protein b and a (C/EBPb and C/
EBPa, respectively), in which uORFs control the expression
ratio of functionally distinct protein isoforms by sensing the
translational status of the cell [116]. Recently, interesting work
using C/EBP uORF mice has corroborated the role of uORFs
in pathophysiology (Table 1). This genetic mouse model has
provided the proof-of-principle for the physiological relevance
of uORF-mediated translational control in mammals [116,117],
as targeted disruption of the uORF initiation codon within the
C/EBPb mRNA resulted in deregulated C/EBPb protein
isoform expression, associated with defective liver regeneration
and impaired osteoclast differentiation [116,117].
Another fascinating regulatory function of uORFs occurs in
transcripts encoded by genes with cryptic promoters—e.g., the
oncoprotein MDM2, which is overexpressed in a number of
human tumors, particularly in osteosarcomas [118]. This
overexpression can result from a change in mRNA structure
due to a switch in promoter usage. There are two transcripts
from the MDM2 gene that differ only in their 59 leader
sequence: a long form (L-MDM2) that carries two uORFs and a
short form (S-MDM2) without uORFs. In these tumors, the
switch in promoter usage yields enhanced cellular levels of the S-
MDM2 mRNA isoform, which is efficiently translated. On the
contrary, the L-MDM2 mRNA is less efficiently transcribed and
its translation is repressed by two functional uORFs [119].
Overall, MDM2 becomes overexpressed in tumors due to the
preferential transcription of the S-MDM2 isoform that is not
under translational regulation (Table 1) [119]. This set of data
illustrates how disrupted uORF-mediated translational regula-
tion can affect expression levels of oncogenes or tumor
suppressor genes, and thus contribute to the pathophysiology
of many forms of cancer.
As previously discussed, uORF-mediated translational regula-
tion has the ability to respond to stress conditions, which is a
feature that can also be associated with human disease. This may
be the case for the beta-site amyloid precursor protein-cleaving
enzyme 1 (BACE1) gene, which encodes an enzyme involved in the
production of beta-amyloid plaques in the brain of patients with
Alzheimer’s disease (AD). The enhanced production of this
enzyme occurs without corresponding changes in BACE1 mRNA
levels and seems to occur at the translational level. The complex
BACE1 59 leader sequence contains three uORFs preceding the
BACE1 initiation codon that might be involved in the enhanced
production of this enzyme characteristic of humans with AD. It
has been hypothesized that aging and other factors such as
cardiovascular disease or traumatic brain injury might impair
brain energy metabolism that leads to a higher phosphorylation of
eIF2a. Indeed, it has been shown that energy deprivation induces
phosphorylation of the eIF2a, which increases the translation of
BACE1 mRNA [73]. Under these conditions, the BACE1 protein
levels might increase due to a uORF(s)-mediated translational
derepression, leading to beta-amyloid overproduction, which
could be an early, initiating molecular mechanism in sporadic
AD (Table 1) [7,8,73,74,120,121]. However, some other data is
consistent with the hypothesis that the translation efficiency of the
BACE1 initiation codon may be increased in patients with AD by
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molecular mechanisms that enhance shunting or increase the
relative accessibility of the BACE1 initiation codon, without the
involvement of uORF(s) [7].
Although phosphorylation of eIF2a in response to cellular stress
has been unequivocally shown to increase BACE1 translation
[73,74], the involvement of uORF(s) in the stress-dependent
mechanism of translation initiation is more controversial
[7,8,120,121]. Indeed, it has been shown that the BACE1 uORF(s)
have little or no effect on BACE1 expression in unstressed cells
[7,8]. Instead, it may be the GC-rich region of the BACE1 59UTR
that forms a constitutive translation barrier, which could prevent
the ribosomes from efficiently translating the BACE1 mRNA [8].
The exact role of the three BACE1 uORFs in its translational
regulation needs further evaluation.
In the examples discussed here, all the uORF-altering
polymorphisms/mutations have been reported in the literature
as demonstrating segregation with the disease. However, some
of them, although present within a gene known to underlie the
disease when disrupted, were not followed up experimentally (by
using reporter assays) to confirm their impact on translational
efficiency (Table 1). In any case, these examples highlight the
importance of searching for uORF changes—in addition to
coding alterations—underlying disease and draw attention to
the need for recognition of these structures as potential
therapeutic targets.
The recent advances in next-generation sequencing technol-
ogies certainly represent a quantum leap toward (i) the
identification of a large number of novel disease-associated
uORF alterations, (ii) the subsequent uncovering of predictive
genotype-phenotype correlations in many areas of human
pathology, and (iii) the recognition of uORFs as possible
therapeutic targets.
Conclusions
It is currently accepted that uORFs may control protein
expression through the involvement of different mechanisms. On
the other hand, emerging data has been showing how uORF-
mediated translational control can affect cell fate decisions.
Although only a limited number of described uORF alterations
have been associated with human disease, it is now clear that such
alterations can be involved in the pathophysiology of different
disorders and in modulating the severity of the individual
phenotype. However, it is our belief that the approaches used to
date have yet to reveal all the mechanisms of translational control
by uORFs. Consequently, further characterization of the mech-
anisms through which altered uORFs might be associated with
human disease will be of great value in the discovery of novel
diagnosis and prognosis biomarkers as well as therapeutic targets,
thereby allowing for the development of new control strategies for
many diseases, including malignancies, metabolic or neurologic
disorders, and inherited syndromes. In addition, the knowledge
gathered from this type of research (namely on the role of uORFs
in the response to external and internal stimuli) will certainly
contribute to a better understanding of the complex network of
interactions leading to homeostasis maintenance and health.
Acknowledgments
The authors would like to thank Joa˜o Lavinha, Alexandre Teixeira, and
Marco Candeias for comments on the manuscript. The authors also thank
Luka Clarke for English editing.
References
1. Morris DR, Geballe AP (2000) Upstream open reading frames as regulators of
mRNA translation. Mol Cell Biol 20: 8635–8642.
2. Calvo SE, Pagliarini DJ, Mootha VK (2009) Upstream open reading frames
cause widespread reduction of protein expression and are polymorphic among
humans. Proc Natl Acad Sci U S A 106: 7507–7512.
3. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC (2004)
Nonsense surveillance regulates expression of diverse classes of mammalian
transcripts and mutes genomic noise. Nat Genet 36: 1073–1078.
4. Wittmann J, Hol EM, Ja¨ck H-M (2006) hUPF2 silencing identifies physiologic
substrates of mammalian nonsense-mediated mRNA decay. Mol Cell Biol 26:
1272–1287.
5. Yepiskoposyan H, Aeschimann F, Nilsson D, Okoniewski M, Muhlemann O
(2011) Autoregulation of the nonsense-mediated mRNA decay pathway in
human cells. RNA 17: 2108–2118.
6. Spriggs KA, Bushell M, Willis AE (2010) Translational regulation of gene
expression during conditions of cell stress. Mol Cell 40: 228–237.
7. Rogers GW Jr, Edelman GM, Mauro VP (2004) Differential utilization of
upstream AUGs in the beta-secretase mRNA suggests that a shunting
mechanism regulates translation. Proc Natl Acad Sci U S A 101: 2794–2799.
8. Lammich S, Scho¨bel S, Zimmer AK, Lichtenthaler SF, Haass C (2004)
Expression of the Alzheimer protease BACE1 is suppressed via its 59-
untranslated region. EMBO Rep 5: 620–625.
9. Suzuki Y, Ishihara D, Sasaki M, Nakagawa H, Hata H, et al. (2000) Statistical
analysis of the 59 untranslated region of human mRNA using ‘‘Oligo-Capped’’
cDNA libraries. Genomics 64: 286–297.
10. Iacono M, Mignone F, Pesole G (2005) uAUG and uORFs in human and
rodent 59 untranslated mRNAs. Gene 349: 97–105.
11. Kochetov AV, Ahmad S, Ivanisenko V, Volkova OA, Kolchanov NA, et al.
(2008) uORFs, reinitiation and alternative translation start sites in human
mRNAs. FEBS Lett 582: 1293–1297.
12. Sathirapongsasuti JF, Sathira N, Suzuki Y, Huttenhower C, Sugano S (2011)
Ultraconserved cDNA segments in the human transcriptome exhibit resistance
to folding and implicate function in translation and alternative splicing. Nucleic
Acids Res 39: 1967–1979.
13. Kozak M (1987) An analysis of 59-noncoding sequences from 699 vertebrate
messenger RNAs. Nucleic Acids Res 15: 8125–4128.
14. Kozak M (1991) An analysis of vertebrate mRNA sequences: intimations of
translational control. J Cell Biol 115: 887–903.
15. Morris DR (1995) Growth control of translation in mammalian cells. Prog
Nucleic Acid Res Mol Biol 51: 339–363.
16. Matsui M, Yachie N, Okada Y, Saito R, Tomita M (2007) Bioinformatic
analysis of post-transcriptional regulation by uORF in human and mouse.
FEBS Lett 581: 4184–4188.
17. Livingstone M, Atas E, Meller A, Sonenberg N (2010) Mechanisms governing
the control of mRNA translation. Phys Biol 7: 021001.
18. Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in
eukaryotes: mechanisms and biological targets. Cell 136: 731–745.
19. Kozak M (1999) Initiation of translation in prokaryotes and eukaryotes. Gene
234: 187–208.
20. Gebauer F, Hentze MW (2004) Molecular mechanisms of translational control.
Nat Rev Mol Cell Biol 5: 827–835.
21. Sachs MS, Geballe AP (2006) Downstream control of upstream open reading
frames. Genes Dev 20: 915–921.
22. Kozak M (1986) Point mutations define a sequence flanking the AUG initiator
codon that modulates translation by eukaryotic ribosomes. Cell 44: 283–292.
23. Kozak M (2002) Pushing the limits of the scanning mechanism for initiation of
translation. Gene 299: 1–34.
24. Meijer HA, Thomas AAM (2002) Control of eukaryotic protein synthesis by
upstream open reading frames in the 59-untranslated region of an mRNA.
Biochem J 367: 1–11.
25. Poyry TAA (2004) What determines whether mammalian ribosomes resume
scanning after translation of a short upstream open reading frame? Genes Dev
18: 62–75.
26. Child SJ, Miller MK, Geballe AP (1999) Translational control by an upstream
open reading frame in the HER-2/neu transcript. J Biol Chem 274: 24335–
24341.
27. Roy B, Vaughn JN, Kim B-H, Zhou F, Gilchrist MA, et al. (2010) The h
subunit of eIF3 promotes reinitiation competence during translation of mRNAs
harboring upstream open reading frames. RNA 16: 748–761.
28. Kozak M (2005) Regulation of translation via mRNA structure in prokaryotes
and eukaryotes. Gene 361: 13–37.
29. Munzarova´ V, Pa´nek J, Gunisˇova´ S, Da´nyi I, Szamecz B, et al. (2011)
Translation reinitiation relies on the interaction between eIF3a/TIF32 and
progressively folded cis-acting mRNA elements preceding short uORFs. PLoS
Genet 7: e1002137. doi:10.1371/journal.pgen.1002137.
30. Lovett PS, Rogers EJ (1996) Ribosome regulation by the nascent peptide.
Microbiol Mol Biol Rev 60: 366–385.
PLOS Genetics | www.plosgenetics.org 10 August 2013 | Volume 9 | Issue 8 | e1003529
31. Geballe AP, Morris DR (1994) Initiation codons within 59-leaders of mRNAs as
regulators of translation. Trends Biochem Sci 19: 159–164.
32. Karagyozov L, Godfrey R, Bo¨hmer SA, Petermann A, Ho¨lters S, et al. (2008)
The structure of the 59-end of the protein-tyrosine phosphatase PTPRJ mRNA
reveals a novel mechanism for translation attenuation. Nucleic Acids Res 36:
4443–4453.
33. Raney A, Law GL, Mize GJ, Morris DR (2002) Regulated translation
termination at the upstream open reading frame in S-adenosylmethionine
decarboxylase mRNA. J Biol Chem 277: 5988–5994.
34. Hayden C, Jorgensen R (2007) Identification of novel conserved peptide uORF
homology groups in Arabidopsis and rice reveals ancient eukaryotic origin of
select groups and preferential association with transcription factor-encoding
genes. BMC Biol 5: 32.
35. Maquat LE, Kinniburgh AJ, Rachmilewitz EA, Ross J (1981) Unstable beta-
globin mRNA in mRNA-deficient betau thalassemia. Cell 27: 543–553.
36. Rehwinkel J, Raes J, Izaurralde E (2006) Nonsense-mediated mRNA decay:
target genes and functional diversification of effectors. Trends Biochem Sci 31:
639–646.
37. Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T (1999) The eukaryotic
polypeptide chain releasing factor (eRF3/GSPT) carrying the translation
termination signal to the 39-Poly(A) tail of mRNA. Direct association of erf3/
GSPT with polyadenylate-binding protein. J Biol Chem 274: 16677–16680.
38. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, et al. (2004) A faux
39-UTR promotes aberrant termination and triggers nonsense-mediated
mRNA decay. Nature 432: 112–118.
39. Behm-Ansmant I, Izaurralde E (2006) Quality control of gene expression: a
stepwise assembly pathway for the surveillance complex that triggers nonsense-
mediated mRNA decay. Genes Dev 20: 391–398.
40. Singh G, Rebbapragada I, Lykke-Andersen J (2008) A competition between
stimulators and antagonists of Upf complex recruitment governs human
nonsense-mediated mRNA decay. PLoS Biol 6: e111. doi:10.1371/journal.
pbio.0060111.
41. Mu¨hlemann O (2008) Recognition of nonsense mRNA: towards a unified
model. Biochem Soc Trans 36: 497–501.
42. Shyu A-B, Wilkinson MF, van Hoof A (2008) Messenger RNA regulation: to
translate or to degrade. EMBO J 27: 471–481.
43. Silva AL, Roma˜o L (2009) The mammalian nonsense-mediated mRNA decay
pathway: to decay or not to decay! Which players make the decision? FEBS
Lett 583: 499–505.
44. Nagy E, Maquat LE (1998) A rule for termination-codon position within
intron-containing genes: when nonsense affects RNA abundance. Trends
Biochem Sci 23: 198–199.
45. Le Hir H, Izaurralde E, Maquat LE, Moore MJ (2000) The spliceosome
deposits multiple proteins 20–24 nucleotides upstream of mRNA exon-exon
junctions. EMBO J 19: 6860–6869.
46. Stalder L, Mu¨hlemann O (2008) The meaning of nonsense. Trends Cell Biol
18: 315–321.
47. Roma˜o L, Ina´cio A, Santos S, Avila M, Faustino P, et al. (2000) Nonsense
mutations in the human beta-globin gene lead to unexpected levels of
cytoplasmic mRNA accumulation. Blood 96: 2895–2901.
48. Ina´cio A, Silva AL, Pinto J, Ji X, Morgado A, et al. (2004) Nonsense mutations
in close proximity to the initiation codon fail to trigger full nonsense-mediated
mRNA decay. J Biol Chem 279: 32170–32180.
49. Silva AL, Pereira FJC, Morgado A, Kong J, Martins R, et al. (2006) The
canonical UPF1-dependent nonsense-mediated mRNA decay is inhibited in
transcripts carrying a short open reading frame independent of sequence
context. RNA 12: 2160–2170.
50. Silva AL, Ribeiro P, Ina´cio A, Liebhaber SA, Roma˜o L (2008) Proximity of the
poly(A)-binding protein to a premature termination codon inhibits mammalian
nonsense-mediated mRNA decay. RNA 14: 563–576.
51. Peixeiro I, Ina´cio Aˆ, Barbosa C, Silva AL, Liebhaber SA, et al. (2012)
Interaction of PABPC1 with the translation initiation complex is critical to the
NMD resistance of AUG-proximal nonsense mutations. Nucleic Acids Res 40:
1160–1173.
52. McGlincy NJ, Tan L-Y, Paul N, Zavolan M, Lilley KS, et al. (2010) Expression
proteomics of UPF1 knockdown in HeLa cells reveals autoregulation of hnRNP
A2/B1 mediated by alternative splicing resulting in nonsense-mediated mRNA
decay. BMC Genomics 11: 565.
53. Zhao C, Datta S, Mandal P, Xu S, Hamilton T (2010) Stress-sensitive
regulation of IFRD1 mRNA decay is mediated by an upstream open reading
frame. J Biol Chem 285: 8552–8562.
54. Davies WL, Vandenberg JI, Sayeed RA, Trezise AE (2004) Post-transcriptional
regulation of the cystic fibrosis gene in cardiac development and hypertrophy.
Biochem Biophys Res Comm 319: 410–418.
55. Nyiko´ T, Sonkoly B, Me´rai Z, Benkovics AH, Silhavy D (2009) Plant upstream
ORFs can trigger nonsense-mediated mRNA decay in a size-dependent
manner. Plant Mol Biol 71: 367–378.
56. Gardner LB (2008) Hypoxic inhibition of nonsense-mediated RNA decay
regulates gene expression and the integrated stress response. Mol Cell Biol 28:
3729–3741.
57. Hinnebusch AG, Dever TE, Asano K (2007) Mechanisms of translation
initiation in the yeast Saccharomyces cerevisiae. In: Mathews M, Sonenberg N,
Hershey JWB, editors. Translational Control in Biology and Medicine. Cold
Spring Harbor, NY: Cold Spring Harbor Laboratory Press. pp 225–268.
58. Raught B, Gingras AC (2007) Signaling to translation initiation. In: Mathews
M, Sonenberg N, Hershey JWB, editors. Translational Control in Biology and
Medicine. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. pp
369–400.
59. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK (1999) Cap-dependent
translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G.
Mol Cell 3: 707–716.
60. Hood HM, Neafsey DE, Galagan J, Sachs MS (2009) Evolutionary roles of
upstream open reading frames in mediating gene regulation in fungi. Annu Rev
Microbiol 63: 85–409.
61. Mueller PP, Hinnebusch AG (1986) Multiple upstream AUG codons mediate
translational control of GCN4. Cell 45: 201–207.
62. Hinnebusch AG (2005) Translational regulation of GCN4 and the general
amino acid control of yeast. Annu Rev Microbiol 59: 407–450.
63. Lewerenz J, Sato H, Albrecht P, Henke N, Noack R, et al. (2011) Mutation of
ATF4 mediates resistance of neuronal cell lines against oxidative stress by
inducing xCT expression. Cell Death Differ 19: 847–858.
64. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, et al. (2004) Activating
transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell
Biol 24: 7469–7482.
65. Ron D, Harding HP (2007) eIF2a phosphorylation in cellular stress responses
and disease. In: Mathews M, Sonenberg N, Hershey JWB, editors.
Translational Control in Biology and Medicine. Cold Spring Harbor, NY:
Cold Spring Harbor Laboratory Press. pp 345–368.
66. Palii SS, Kays CE, Deval C, Bruhat A, Fafournoux P, et al. (2009) Specificity of
amino acid regulated gene expression: analysis of genes subjected to either
complete or single amino acid deprivation. Amino Acids 37: 79–88.
67. Watatani Y, Ichikawa K, Nakanishi N, Fujimoto M, Takeda H, et al. (2008)
Stress-induced translation of ATF5 mRNA is regulated by the 59-untranslated
region. J Biol Chem 283: 2543–2553.
68. Hansen MB, Mitchelmore C, Kjaerulff KM, Rasmussen TE, Pedersen KM, et
al. (2002) Mouse Atf5: molecular cloning of two novel mRNAs, genomic
organization, and odorant sensory neuron localization. Genomics 80: 344–350.
69. Lohse I, Reilly P, Zaugg K (2011) The CPT1C 59UTR contains a repressing
upstream open reading frame that is regulated by cellular energy availability
and AMPK. PLoS ONE 6: e21486. doi:10.1371/journal.pone.0021486.
70. Palam LR, Baird TD, Wek RC (2011) Phosphorylation of eIF2 facilitates
ribosomal bypass of an inhibitory upstream ORF to enhance CHOP
translation. J Biol Chem 286: 10939–10949.
71. Chen Y-J, Tan BC-M, Cheng Y-Y, Chen J-S, Lee S-C (2010) Differential
regulation of CHOP translation by phosphorylated eIF4E under stress
conditions. Nucleic Acids Res 38: 764–777.
72. Lee Y-Y, Cevallos RC, Jan E (2008) An upstream open reading frame regulates
translation of GADD34 during cellular stresses that induce eIF2 phosphory-
lation. J Biol Chem 284: 6661–6673.
73. O’Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, et al. (2008)
Phosphorylation of the translation initiation factor eIF2a increases BACE1
levels and promotes amyloidogenesis. Neuron 60: 988–1009.
74. Mouton-Liger F, Paquet C, Dumurgier J, Bouras C, Pradier L, et al. (2012)
Oxidative stress increases BACE1 protein levels through activation of the PKR-
eIF2a pathway. Biochim Biophys Acta 1822: 885–896.
75. Raveh-Amit H, Maissel A, Poller J, Marom L, Elroy-Stein O, et al. (2009)
Translational control of protein kinase C by two upstream open reading
frames. Mol Cell Biol 29: 6140–6148.
76. van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Koritzinsky M,
et al. (2007) Regulation of Cited2 expression provides a functional link between
translational and transcriptional responses during hypoxia. Radiother Oncol
83: 346–352.
77. Bastide A, Karaa Z, Bornes S, Hieblot C, Lacazette E, et al. (2008) An
upstream open reading frame within an IRES controls expression of a specific
VEGF-A isoform. Nucleic Acids Res 3: 2434.
78. Gopfert U, Kullmann M, Hengst L (2003) Cell cycle-dependent translation of
p27 involves a responsive element in its 59-UTR that overlaps with a uORF.
Hum Mol Genet 12: 1767–1779.
79. Park E-H, Lee JM, Blais JD, Bell JC, Pelletier J (2005) Internal translation
initiation mediated by the angiogenic factor Tie2. J Biol Chem 280: 20945–
20953.
80. Grobe K, Esko JD (2002) Regulated translation of heparan sulfate N-
acetylglucosamine N-deacetylase/N-sulfotransferase isozymes by structured 59-
untranslated regions and internal ribosome entry sites. J Biol Chem 277:
30699–30706.
81. Fernandez J, Yaman I, Sarnow P, Snider MD, Hatzoglou M (2002) Regulation
of internal ribosomal entry site-mediated translation by phosphorylation of the
translation initiation factor eIF2alpha. J Biol Chem 277: 19198–19205.
82. Yaman I, Fernandez J, Liu H, Caprara M, Komar AA, et al. (2003) The zipper
model of translational control: a small upstream ORF is the switch that controls
structural remodeling of an mRNA leader. Cell 113: 519–531.
83. O¨rd T, O¨rd D, Ko˜ivoma¨gi M, Juhkam K, O¨rd T (2009) Human TRB3 is
upregulated in stressed cells by the induction of translationally efficient mRNA
containing a truncated 59-UTR. Gene 444: 24–32.
84. Koschmieder S, D’Alo F, Radomska H, Schoneich C, Chang JS, et al. (2007)
CDDO induces granulocytic differentiation of myeloid leukemic blasts through
translational up-regulation of p42 CCAAT enhancer binding protein alpha.
Blood 110: 3695–3705.
PLOS Genetics | www.plosgenetics.org 11 August 2013 | Volume 9 | Issue 8 | e1003529
85. Re A, Hamel N, Fu C, Bush H, McCaffrey T, et al. (2001) A link between
diabetes and atherosclerosis: glucose regulates expression of CD36 at the level
of translation. Nat Med 7: 840–846.
86. Mehta A (2006) Derepression of the Her-2 uORF is mediated by a novel post-
transcriptional control mechanism in cancer cells. Genes Dev 20: 939–953.
87. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the
NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.
88. Bersano A, Ballabio E, Bresolin N, Candelise L (2008) Genetic polymorphisms
for the study of multifactorial stroke. Hum Mutat 29: 776–795.
89. Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, et al. (2008)
Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII
C46T gene polymorphism and coronary risk. J Thromb Haemost 6: 291–296.
90. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, et al. (1998) A
common genetic polymorphism (46 C to T substitution) in the 59-untranslated
region of the coagulation factor XII gene is associated with low translation
efficiency and decrease in plasma factor XII level. Blood 91: 2010–2014.
91. Oner R, Agarwal S, Dimovski AJ, Efremov GD, Petkov GH, et al. (1991) The
G to A mutation at position +22 39 to the Cap site of the beta-globin gene as a
possible cause for a beta-thalassemia. Hemoglobin 15: 67–76.
92. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, et al. (2002)
Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.
Nat Genet 32: 285–289.
93. Poulat F, Desclozeaux M, Tuffery S, Jay P, Boizet B, et al. (1998) Mutation in
the 59 noncoding region of the SRY gene in an XY sex-reversed patient. Hum
Mutat Suppl 1: S192–194.
94. Witt H, Luck W, Hennies HC, Classen M, Kage A, et al. (2000) Mutations in
the gene encoding the serine protease inhibitor, Kazal type 1 are associated
with chronic pancreatitis. Nat Genet 25: 213–216.
95. Liu L, Dilworth D, Gao L, Monzon J, Summers A, et al. (1999) Mutation of the
CDKN2A 59 UTR creates an aberrant initiation codon and predisposes to
melanoma. Nat Genet 21: 128–132.
96. Bisio A, Nasti S, Jordan JJ, Gargiulo S, Pastorino L, et al. (2010) Functional
analysis of CDKN2A/p16INK4a 59-UTR variants predisposing to melanoma.
Hum Mol Genet 19: 1479–1491.
97. So¨zen MM, Whittall R, Oner C, Tokatli A, Kalkanog˘lu HS, et al. (2005) The
molecular basis of familial hypercholesterolaemia in Turkish patients.
Atherosclerosis 180: 63–71.
98. Lukowski SW, Bombieri C, Trezise AEO (2011) Disrupted posttranscriptional
regulation of the cystic fibrosis transmembrane conductance regulator (CFTR)
by a 59UTR mutation is associated with a CFTR-related disease. Hum Mutat
32: e2266–e2282.
99. Huopio H, Ja¨a¨skela¨inen J, Komulainen J, Miettinen R, Ka¨rkka¨inen P, et al.
(2002) Acute insulin response tests for the differential diagnosis of congenital
hyperinsulinism. J Clin Endocrinol Metab 87: 4502–4507.
100. Braverman N, Chen L, Lin P, Obie C, Steel G, et al. (2002) Mutation analysis
of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and
functional correlations of genotype with phenotype. Hum Mutat 20: 284–297.
101. Krude H, Biebermann H, Luck W, Horn R, Brabant G, et al. (1998) Severe
early-onset obesity, adrenal insufficiency and red hair pigmentation caused by
POMC mutations in humans. Nat Genet 19:155–157.
102. Tassin J, Du¨rr A, Bonnet AM, Gil R, Vidailhet M, et al. (2000) Levodopa-
responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123:
1112–1121.
103. Rideau A, Mangeat B, Matthes T, Trono D, Beris P. (2007) Molecular
mechanism of hepcidin deficiency in a patient with juvenile hemochromatosis.
Haematologica 92: 127–128.
104. Wen Y, Liu Y, Xu Y, Zhao Y, Hua R, et al. (2009) Loss-of-function mutations
of an inhibitory upstream ORF in the human hairless transcript cause Marie
Unna hereditary hypotrichosis. Nat Genet 41: 228–233.
105. Baek IC, Kim JK, Cho K-H, Cha D-S, Cho J-W, et al. (2009). A novel
mutation in Hr causes abnormal hair follicle morphogenesis in hairpoor mouse,
an animal model for Marie Unna Hereditary Hypotrichosis. Mamm Genome
20: 350–358.
106. Cazzola M, Skoda RC (2000) Translational pathophysiology: a novel
molecular mechanism of human disease. Blood 95: 3280–3288.
107. Kikuchi M, Tayama T, Hayakawa H, Takahashi I, Hoshino H, et al. (1995)
Familial thrombocytosis. Br J Haematol 89: 900–902.
108. Ghilardi N, Skoda RC (1999) A single-base deletion in the thrombopoietin
(TPO) gene causes familial essential thrombocythemia through a mechanism of
more efficient translation of TPO mRNA. Blood 94: 1480–1482.
109. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC (1999) Hereditary
thrombocythaemia in a Japanese family is caused by a novel point mutation in
the thrombopoietin gene. Br J Haematol 107: 310–316.
110. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC (1998) An activating
splice donor mutation in the thrombopoietin gene causes hereditary
thrombocythaemia. Nat Genet 18: 49–52.
111. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, et al. (1998) Familial
essential thrombocythemia associated with one-base deletion in the 59-
untranslated region of the thrombopoietin gene. Blood 92: 1091–1096.
112. Sivagnanasundaram S, Morris AG, Gaitonde EJ, McKenna PJ, Mollon JD, et
al. (2000) A cluster of single nucleotide polymorphisms in the 59-leader of the
human dopamine D3 receptor gene (DRD3) and its relationship to
schizophrenia. Neurosci Lett 279: 13–16.
113. Pasaje CF, Bae JS, Park BL, Cheong HS, Kim JH, et al. (2012) HWDR46 is a
genetic risk factor for aspirin-exacerbated respiratory disease in a Korean
population. Allergy Asthma Immunol Res 4: 199–205.
114. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, et al. (2005)
Regulatory mutations in transforming growth factor-beta3 gene cause
arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res
65: 366–373.
115. Niesler B, Flohr T, No¨then MM, Fischer C, Rietschel M, et al. (2001)
Association between the 59 UTR variant C178T of the serotonin receptor
gene HTR3A and bipolar affective disorder. Pharmacogenetics 11: 471–
475.
116. Wethmar K, Smink JJ, Leutz A (2010) Upstream open reading frames:
Molecular switches in (patho)physiology. Bioessays 32: 885–893.
117. Wethmar K, Begay V, Smink JJ, Zaragoza K, Wiesenthal V, et al. (2010) C/
EBP uORF mice: a genetic model for uORF-mediated translational control in
mammals. Genes Dev 24: 15–20.
118. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992)
Amplification of a gene encoding a p53-associated protein in human sarcomas.
Nature 358: 80–83.
119. Brown CY, Mize GJ, Pineda M, George DL, Morris DR (1999) Role of two
upstream open reading frames in the translational control of oncogene mdm2.
Oncogene 18: 5631–5637.
120. Zhou W, Song W (2006) Leaky scanning and reinitiation regulate BACE1 gene
expression. Mol Cell Biol 26: 3353–3364.
121. Mihailovich M, Thermann R, Grohovaz F, Hentze MW, Zacchetti D (2007)
Complex translational regulation of BACE1 involves upstream AUGs and
stimulatory elements within the 59 untranslated region. Nucleic Acids Res 35:
2975–2985.
PLOS Genetics | www.plosgenetics.org 12 August 2013 | Volume 9 | Issue 8 | e1003529
